Effect of aripitan combined with dexamethasone sodium phosphate and panolosetron in prevention of nausea and vomiting after chemotherapy for osteosarcoma

Objective To observe the efficacy and safety of aripitan combined with dexamethasone sodium phosphate and panolosetron in preventing nausea and vomiting of patients with osteosarcoma after chemotherapy with cisplatin, epirubicin hydrochloride and ifosfamide. Methods A total of osteosarcoma patients who were given cisplatin plus epirubicin hydrochloride plus ifosfamide for chemotherapy were randomly divided into aripitan group(n=99)with triple antiemetic program and control group(n=98)with two antiemetic drug in combination. The complete response(CR)rates of nausea and vomiting and occurrence of adverse reactions at 0~24 h and >24~144 h were observed before chemotherapy, the first three times and latter three times of postoperative chemotherapies in the two groups were also observed. Results The complete remission rates in the aripitan group and control group were 75.76% and 70.41%, respectively at 0~24 h after chemotherapy, and no significant difference were observed(P>0.05), and 68.69% and 54.08%, respectively at >24~144 h, which showed significant difference(P<0.05). The complete remission rates in the aripitan group and control group were 67.68% and 61.22%, respectively at 0~24 h after the first three chemotherapies, but no significant difference were observed(P>0.05), and 59.60% and 44.90% - at >24~144 h, which showed significant difference(P<0.05). The complete remission rates in the aripitan group and control group were 52.53% and 50.00%, respectively at 0~24 h after latter three times of chemotherapies, there were no significant differences between the two groups(P>0.05), and were 46.46% and 32.65%, respectively at >24~144 h in the two groups, which showed significant difference(P<0.05). There were no differences before chemotherapy, after the first three times of chemotherapies and latter three times of chemotherapies in the incidence of adverse reactions between the two groups(P>0.05), but the incidence of adverse reactions in the aripitan group was slightly higher than that in the control group. Conclusion Aripitan combined with palonosetron hydrochloride and dexamethasone sodium phosphate has no significant effect on nausea and vomiting within 0~24 h after chemotherapy, and has a significant effect within >24~144 h. Besides, it has better efficacy, but the therapeutic effect gradually decreases with the repeated chemotherapies.